News
23h
Zacks Investment Research on MSNBSX vs. MDT: Which MedSurg Stock Is the Better Investment Now?Investors are increasingly eyeing the fast-growing MedSurg equipment space, which is projected to witness a compound annual growth rate (CAGR) of 9.54% from 2025 to 2030 (per Grand View Research). Two ...
Lumen-apposing metal stents. LAMS used in this study (Hot AXIOS stent and electrocautery-enhanced delivery system, Boston Scientific, Natick, Massachusetts, USA) were through-the-scope, fully covered ...
The median CBD diameter of patients who underwent successful EUS-BD was 16 mm (IQR 13–18 mm) and CBD measured 11 mm in patient treated by rendezvous drainage. Choledochoduodenostomy was undertaken via ...
Boston Scientific's stock surged 58% over the past year, ... featuring devices like the AXIOS Stent for pancreatic drainage and the Lumenis Pulse Laser System for kidney stones.
Boston Scientific has struck a deal to buy medical-device maker Silk Road Medical for about $1.26 billion, adding a technology for stroke prevention to its vascular portfolio.
Boston Scientific BSX is gaining market share across all segments. New regulatory approvals and accretive acquisitions bode well for long-term growth. The stock carries a Zacks Rank #2 (Buy ...
Boston Scientific Corp. agreed to pay $71 a share in cash for medical technology firm Axonics Inc., a maker of devices to treat urinary and bowel dysfunction. The purchase price comes to an equity ...
A drug-coated balloon made by Boston Scientific reduced the risk of heart attack in patients with complications from stents, researchers reported on Wednesday. Boston Scientific hopes to use this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results